• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Metastatic castration-resistant prostate cancer therapy: the quest for the perfect molecule.

作者信息

Bianco Davide, Nappi Carmela, Klain Michele

机构信息

Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.

出版信息

Eur J Nucl Med Mol Imaging. 2024 Feb;51(3):883-884. doi: 10.1007/s00259-023-06506-8.

DOI:10.1007/s00259-023-06506-8
PMID:37987784
Abstract
摘要

相似文献

1
Metastatic castration-resistant prostate cancer therapy: the quest for the perfect molecule.转移性去势抵抗性前列腺癌治疗：对完美分子的探索。
Eur J Nucl Med Mol Imaging. 2024 Feb;51(3):883-884. doi: 10.1007/s00259-023-06506-8.
2
Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.反驳观点：在有症状的转移性去势抵抗性前列腺癌中，多西他赛和镭-223应首先使用哪一种？镭-223是骨转移为主的有症状转移性去势抵抗性前列腺癌的首选治疗方法。
Clin Adv Hematol Oncol. 2015 May;13(5):293-8.
3
[Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.[镥]-PSMA-617 放射性核素治疗转移性去势抵抗性前列腺癌患者（LuPSMA 试验）：一项单中心、单臂、2 期研究。
Lancet Oncol. 2018 Jun;19(6):825-833. doi: 10.1016/S1470-2045(18)30198-0. Epub 2018 May 8.
4
Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Docetaxel still the optimal first choice for symptomatic metastatic castration-resistant prostate cancer.对立观点：在有症状的转移性去势抵抗性前列腺癌中，多西他赛和镭-223哪个应首先使用？多西他赛仍是有症状的转移性去势抵抗性前列腺癌的最佳首选。
Clin Adv Hematol Oncol. 2015 May;13(5):293-5.
5
Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer.Bi-PSMA-617靶向α放射性核素疗法治疗转移性去势抵抗性前列腺癌
Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1099-1100. doi: 10.1007/s00259-017-3657-9. Epub 2017 Mar 2.
6
Predictive Factors of Response and Overall Survival in Patients with Castration-Resistant Metastatic Prostate Cancer Undergoing Lu-PSMA Therapy.接受镥-PSMA治疗的去势抵抗性转移性前列腺癌患者反应和总生存期的预测因素
J Nucl Med. 2018 Jul;59(7):1033-1034. doi: 10.2967/jnumed.118.209270. Epub 2018 Apr 13.
7
Exceptional 4-year response to Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer.镥-PSMA放射性配体疗法对转移性去势抵抗性前列腺癌产生了长达4年的卓越疗效。
Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):2212-2213. doi: 10.1007/s00259-019-04410-8. Epub 2019 Jul 4.
8
177Lu-PSMA and 177Lu-DOTATATE Therapy in a Patient With Metastatic Castration-Resistant Prostate Cancer and Neuroendocrine Differentiation.镥-177 前列腺特异性膜抗原与镥-177 奥曲肽治疗转移性去势抵抗性前列腺癌伴神经内分泌分化
Clin Nucl Med. 2019 Dec;44(12):978-980. doi: 10.1097/RLU.0000000000002824.
9
When to initiate treatment with radium-223 in patients with metastatic castration-resistant prostate cancer.
Clin Adv Hematol Oncol. 2016 Jan;14(1):26-9.
10
Acute Promyelocytic Leukemia After Treatment of Metastatic Castration-Resistant Prostate Cancer With Radium-223.用镭-223治疗转移性去势抵抗性前列腺癌后发生的急性早幼粒细胞白血病
Clin Genitourin Cancer. 2017 Jun;15(3):e501-e502. doi: 10.1016/j.clgc.2016.12.028. Epub 2016 Dec 29.

本文引用的文献

1
A phase 1 trial to determine the maximum tolerated dose and patient-specific dosimetry of [Lu]Lu-LNC1003 in patients with metastatic castration-resistant prostate cancer.一项评估 [Lu]Lu-LNC1003 在转移性去势抵抗性前列腺癌患者中的最大耐受剂量和患者特异性剂量学的 1 期临床试验。
Eur J Nucl Med Mol Imaging. 2024 Feb;51(3):871-882. doi: 10.1007/s00259-023-06470-3. Epub 2023 Oct 21.
2
Emerging Role of Nuclear Medicine in Prostate Cancer: Current State and Future Perspectives.核医学在前列腺癌中的新兴作用：现状与未来展望
Cancers (Basel). 2023 Sep 27;15(19):4746. doi: 10.3390/cancers15194746.
3
Clinical Experience with [Ac]Ac-PSMA Treatment in Patients with [Lu]Lu-PSMA-Refractory Metastatic Castration-Resistant Prostate Cancer.
在 [Lu]Lu-PSMA 难治性转移性去势抵抗性前列腺癌患者中使用 [Ac]Ac-PSMA 治疗的临床经验。
J Nucl Med. 2023 Oct;64(10):1574-1580. doi: 10.2967/jnumed.123.265546. Epub 2023 Aug 24.
4
Diagnosis, Management and Theragnostic Approach of Gastro-Entero-Pancreatic Neuroendocrine Neoplasms.胃肠胰神经内分泌肿瘤的诊断、管理及诊疗一体化方法
Cancers (Basel). 2023 Jul 4;15(13):3483. doi: 10.3390/cancers15133483.
5
Development of [Lu]Lu-LNC1003 for radioligand therapy of prostate cancer with a moderate level of PSMA expression.开发[Lu]Lu-LNC1003 用于 PSMA 表达中等水平的前列腺癌放射性配体治疗。
Eur J Nucl Med Mol Imaging. 2023 Jul;50(9):2846-2860. doi: 10.1007/s00259-023-06229-w. Epub 2023 Apr 25.
6
Biodistribution and dosimetry for combined [Lu]Lu-PSMA-I&T/[Ac]Ac-PSMA-I&T therapy using multi-isotope quantitative SPECT imaging.联合[Lu]Lu-PSMA-I&T/[Ac]Ac-PSMA-I&T 治疗的生物分布和剂量学：使用多同位素定量 SPECT 成像。
Eur J Nucl Med Mol Imaging. 2023 Apr;50(5):1280-1290. doi: 10.1007/s00259-022-06092-1. Epub 2023 Jan 11.
7
Initial Testing of an Approximated, Fast Calculation Procedure for Personalized Dosimetry in Radionuclide Therapy Based on Planar Whole-Body Scan and Monte-Carlo Specific Dose Rates from the Project.基于平面全身扫描和该项目的蒙特卡洛特定剂量率，对放射性核素治疗中个性化剂量测定的近似快速计算程序进行初步测试。
Life (Basel). 2022 Aug 25;12(9):1303. doi: 10.3390/life12091303.
8
Combined bone scintigraphy and fluorocholine PET/computed tomography predicts response to radium-223 therapy in patients with prostate cancer.联合骨闪烁扫描和氟胆碱正电子发射断层扫描/计算机断层扫描可预测前列腺癌患者对镭-223治疗的反应。
Future Sci OA. 2021 May 21;7(8):FSO719. doi: 10.2144/fsoa-2021-0053. eCollection 2021 Sep.
9
Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer.镭-223 二氯化物治疗转移性去势抵抗性前列腺癌的真实世界结局。
Future Oncol. 2020 Jul;16(19):1371-1384. doi: 10.2217/fon-2020-0039. Epub 2020 May 29.
10
Single Low-Dose Injection of Evans Blue Modified PSMA-617 Radioligand Therapy Eliminates Prostate-Specific Membrane Antigen Positive Tumors.单次低剂量注射 Evans Blue 修饰的 PSMA-617 放射性配体疗法可消除前列腺特异性膜抗原阳性肿瘤。
Bioconjug Chem. 2018 Sep 19;29(9):3213-3221. doi: 10.1021/acs.bioconjchem.8b00556. Epub 2018 Aug 22.